trial,pubID,pseudogroup,weeks,group,IgD-/IgM-/IgA-/IgG+/Antigen++ B cells
G002,G002-931,G002,16,3,19377.0
G002,G002-997,G002,16,3,13291.0
G002,G002-852,G002,16,1,18442.0
G002,G002-616,G002,16,1,12306.0
G002,G002-678,G002,16,1,9167.0
G002,G002-884,G002,16,3,12803.0
G002,G002-796,G002,16,3,7100.0
G002,G002-595,G002,16,3,6427.0
G002,G002-988,G002,16,3,5149.0
G002,G002-905,G002,16,1,7305.0
G002,G002-632,G002,16,3,3102.0
G002,G002-619,G002,16,1,7951.0
G002,G002-546,G002,16,1,6267.0
G002,G002-304,G002,16,3,2058.0
G002,G002-477,G002,16,3,3760.0
G002,G002-371,G002,16,3,2499.0
G002,G002-866,G002,16,3,9280.0
G002,G002-516,G002,16,1,2151.0
G002,G002-758,G002,16,1,1855.0
G002,G002-969,G002,16,1,4452.0
G002,G002-302,G002,16,1,5081.0
G002,G002-427,G002,16,3,1604.0
G002,G002-278,G002,16,3,1505.0
G002,G002-462,G002,16,3,1344.0
G002,G002-825,G002,16,3,1362.0
G002,G002-810,G002,16,3,2525.0
G002,G002-813,G002,16,1,962.0
G002,G002-834,G002,16,1,275.0
